RDHL

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.08
Percentage change 4.30	%

Peers: BCRX GERN AXSM AMRN FATE ARDX LGND ACAD MNKD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.50%	Shs Outstand	2.29M	Perf Week	2.65%
Market Cap	4.44M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.28M	Perf Month	10.23%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	4.26%	Short Float	2.77%	Perf Quarter	-30.47%
Income	-	P/S	-	EPS this Y	-	Inst Trans	16.08%	Short Ratio	0.29	Perf Half Y	-69.45%
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf YTD	-68.76%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	20.27 -90.43%	Perf Year	-79.15%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	85.26% 65.76%	ROIC	-	52W Low	1.71 13.45%	Perf 3Y	-99.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-54.50% 5.07%	Gross Margin	-	Volatility	5.64% 4.90%	Perf 5Y	-99.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	94.66%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	102.33%	SMA20	2.44%	Beta	4.21	Target Price	1000.00
Payout	-	Debt/Eq	-	Sales Q/Q	-90.21%	SMA50	-1.36%	Rel Volume	0.07	Prev Close	1.86
Employees	35	LT Debt/Eq	-	Earnings	-	SMA200	-62.46%	Avg Volume	216.78K	Price	1.94
IPO	Jan 07, 2013	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	14,294	Change	4.30%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-21	Initiated	Cantor Fitzgerald	Overweight	$22
May-18-21	Initiated	H.C. Wainwright	Buy	$23
Sep-11-20	Initiated	BTIG Research	Buy
Jul-12-19	Upgrade	WBB Securities	Buy → Strong Buy
Mar-12-19	Upgrade	WBB Securities	Speculative Buy → Buy
Jan-26-18	Initiated	Nomura	Buy	$18
Oct-06-17	Initiated	Seaport Global Securities	Buy	$19
Oct-04-17	Reiterated	H.C. Wainwright	Buy	$33 → $36
Feb-24-17	Reiterated	FBR & Co.	Outperform	$36 → $25
Jul-27-16	Reiterated	FBR Capital	Outperform	$33 → $36
Sep-29-15	Initiated	Nomura	Buy
Jul-29-15	Reiterated	ROTH Capital	Buy	$30 → $31
Jun-17-15	Reiterated	H.C. Wainwright	Buy	$23 → $32
Jun-15-15	Reiterated	ROTH Capital	Buy	$27.50 → $30

Show Previous Ratings

May-13-25 07:00AM	RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win (PR Newswire) -5.50%
May-02-25 07:00AM	RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress (PR Newswire)
Apr-28-25 07:03AM	RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 (PR Newswire) -9.96%
Apr-17-25 04:01PM	RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency (PR Newswire) +9.18%
Apr-16-25 07:00AM	RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption (PR Newswire)
07:48AM	Loading…
Apr-10-25 07:48AM	RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights (PR Newswire)
Mar-18-25 07:00AM	RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation (PR Newswire)
Mar-12-25 07:00AM	RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results (PR Newswire)
Feb-27-25 07:00AM	RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum (PR Newswire) -6.49%
Feb-26-25 10:36AM	RedHill and Hyloris sign agreement for Bekindas development (Pharmaceutical Technology) -9.41%
Feb-25-25 07:00AM	RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties (PR Newswire) -11.83%
Feb-05-25 06:45AM	RedHill Biopharma launches trial of combination therapy for prostate cancer (Clinical Trials Arena)
Feb-04-25 07:00AM	RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer (PR Newswire)
Jan-21-25 07:00AM	RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published (PR Newswire) +12.30%
Dec-10-24 07:00AM	Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development (PR Newswire) +8.77%
07:18AM	Loading…
Dec-03-24 07:18AM	RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court (TipRanks) -5.74%
Dec-02-24 07:00AM	RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court (PR Newswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-28-24 07:00AM	RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND (PR Newswire)
Oct-23-24 07:29AM	RedHill Biopharma and Duke Collaborate on Opaganib Development (TipRanks)
Oct-22-24 07:00AM	RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury (PR Newswire)
Oct-14-24 07:00AM	RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment (PR Newswire)
Oct-01-24 07:27AM	RedHill Biopharma Secures Opaganib COVID-19 Patent (TipRanks) -5.04%
07:00AM	RedHill and Medi-Cal Deal Maintains Talicia Reimbursement Without Prior Authorization for 15 Million Californians (PR Newswire)
Sep-30-24 07:00AM	RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041 (PR Newswire)
Sep-09-24 07:00AM	RedHill's Talicia Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines (PR Newswire) +9.81%
Sep-05-24 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Sep-03-24 07:00AM	New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality (PR Newswire)
Aug-29-24 07:00AM	RedHill Biopharma Announces First Half 2024 Business Highlights (PR Newswire)
Aug-26-24 07:00AM	RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma (PR Newswire) -6.54%
07:00AM	Loading…
Aug-21-24 07:00AM	Talicia Launched in the United Arab Emirates (PR Newswire) +25.06%
Aug-19-24 07:56AM	Upcoming Stock Splits This Week (August 19 to August 23) Stay Invested (TipRanks) +10.69%
07:00AM	RedHill Announces Positive Obesity and Diabetes Results with Opaganib (PR Newswire)
Aug-16-24 07:00AM	RedHill Biopharma Announces Plan to Implement ADS Ratio Change (PR Newswire) -22.64%
Aug-01-24 07:00AM	Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease (PR Newswire) +97.87%
Jul-22-24 07:00AM	RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia Lien (PR Newswire) +5.09%
Jul-09-24 08:00AM	RedHill Biopharma Terminates License Agreement for Aemcolo (PR Newswire)
Jun-03-24 07:00AM	RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 (PR Newswire)
May-06-24 07:43AM	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib (MT Newswires)
07:00AM	RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 (PR Newswire)
Apr-24-24 07:00AM	RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study (PR Newswire)
Apr-08-24 09:23AM	RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights (PR Newswire)
Apr-02-24 07:00AM	RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price (PR Newswire)
Mar-11-24 07:00AM	RedHill Announces New USPTO Patent Covering Talicia Through 2034 (PR Newswire)
Mar-05-24 07:00AM	RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs (PR Newswire) -7.48%
Feb-20-24 07:00AM	RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication (PR Newswire)
Jan-26-24 12:46PM	RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering (PR Newswire)
Jan-25-24 09:05AM	RedHill Biopharma Announces $8 Million Registered Direct Offering (PR Newswire) -39.85%
06:00AM	RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042 (PR Newswire)
Dec-20-23 08:45AM	RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola (PR Newswire) +6.06%
Dec-12-23 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Dec-04-23 07:00AM	RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study (PR Newswire) +13.86%
Dec-03-23 01:11PM	5 Most Volatile Stocks Under $5 For Day Trading (Insider Monkey)
Nov-30-23 09:08AM	Why Is Redhill Biopharma (RDHL) Stock Down 27% Today? (InvestorPlace) -30.56%
Nov-27-23 01:41PM	5 Investors Betting Big on RedHill Biopharma (RDHL) Stock (InvestorPlace) +216.96%
07:00AM	RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034 (PR Newswire)
Nov-14-23 08:00AM	RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market (PR Newswire) +9.00%
Oct-03-23 07:00AM	RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study (PR Newswire) -14.86%
Sep-22-23 04:15PM	RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire) -11.11%
Sep-18-23 07:00AM	RedHill Announces FDA sNDA Approval for Talicia® (PR Newswire)
Sep-05-23 07:00AM	RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®) (PR Newswire)
Aug-17-23 07:00AM	RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights (PR Newswire) +13.41%
Aug-01-23 07:00AM	RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. (PR Newswire)
Jul-31-23 07:00AM	RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA (PR Newswire)
Jul-25-23 03:58PM	RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise (PR Newswire)
Jul-21-23 09:33AM	RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds (PR Newswire) -25.95%
07:00AM	RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development (PR Newswire)
Jun-12-23 08:00AM	RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights (PR Newswire)
May-22-23 07:00AM	RedHill Provides R&D Update (PR Newswire)
May-15-23 06:17PM	RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency (PR Newswire) -5.02%
May-09-23 07:00AM	RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week (PR Newswire)
May-01-23 07:00AM	RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting (PR Newswire) -8.02%
Apr-28-23 07:00AM	RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights (PR Newswire) +6.58%
Apr-17-23 07:39AM	Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet (Simply Wall St.)
Apr-11-23 07:00AM	RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -5.76%
Apr-03-23 01:26PM	RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering (PR Newswire)
Mar-30-23 08:00AM	RedHill Biopharma Announces $6 Million Registered Direct Offering (PR Newswire) -6.33%
Mar-23-23 07:32AM	RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt (Simply Wall St.) -18.51%
Mar-21-23 07:00AM	RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders (PR Newswire)
Mar-16-23 06:15PM	RedHill Biopharma Announces Plan to Implement ADS Ratio Change (PR Newswire) -24.28%
Mar-08-23 07:05PM	RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor (PR Newswire)
Feb-28-23 08:01AM	RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development (ACCESSWIRE)
07:00AM	RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program (PR Newswire)
Feb-16-23 08:01AM	RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan (ACCESSWIRE) +6.07%
08:00AM	RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support (PR Newswire)
Feb-15-23 07:00AM	RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome (PR Newswire)
Feb-10-23 03:10PM	Raleigh pharma sheds debt in exchange for top-selling drug. Now what? (American City Business Journals)
Feb-06-23 07:00AM	RedHill Biopharma and HealthCare Royalty Agree to Extinguish All RedHill's Debt Obligations in Exchange for Movantik® (PR Newswire) +12.90%
Jan-26-23 07:00AM	RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease (PR Newswire)
Jan-03-23 11:07AM	RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study (Benzinga) +26.16%
07:00AM	RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19 (PR Newswire)
Dec-27-22 02:53PM	2022 Year in Review: Layoffs hit Triangle biotech, pharma companies (American City Business Journals) -13.06%
Dec-07-22 09:45AM	Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL) (ACCESSWIRE)
Dec-06-22 01:36PM	RedHill Biopharma Closes $8.0 Million Underwritten Public Offering (PR Newswire) -10.11%
Dec-02-22 09:00AM	RedHill Biopharma Prices $8.0 Million Underwritten Public Offering (PR Newswire) -27.21%
Dec-01-22 04:01PM	RedHill Biopharma Announces Proposed Public Offering (PR Newswire)
Nov-29-22 08:00AM	RedHill Biopharma Announces Q3/22 Results and Operational Highlights (PR Newswire) -6.13%
Nov-24-22 05:19AM	The RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Just Cut Their Revenue Forecast By 23% (Simply Wall St.)
Nov-17-22 08:30AM	RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury (PR Newswire)
Nov-15-22 03:09PM	RedHill Biopharma set to lose key revenue source, could 'cease operations' (American City Business Journals)

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Redhill Biopharma Ltd. ADR

Upgrade your FINVIZ experience